Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ainos, Inc. stock logo
AIMD
Ainos
$4.01
+3.6%
$3.45
$2.00
$5.00
$19.13M2.25830,296 shs89,210 shs
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
$0.76
+0.6%
$0.71
$0.61
$3.02
$36.08M3.24623,154 shs986,012 shs
LAVA Therapeutics N.V. stock logo
LVTX
LAVA Therapeutics
$1.58
-2.5%
$1.54
$0.85
$2.09
$41.56M0.5223,362 shs71,013 shs
VolitionRx Limited stock logo
VNRX
VolitionRx
$0.65
-0.3%
$0.65
$0.40
$0.94
$69.72M1.27200,549 shs193,514 shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ainos, Inc. stock logo
AIMD
Ainos
+0.26%+11.85%+10.89%+21.32%+57.93%
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
+8.57%+13.43%+12.06%-28.30%-23.05%
LAVA Therapeutics N.V. stock logo
LVTX
LAVA Therapeutics
+0.62%+3.85%+3.18%+19.12%-4.14%
VolitionRx Limited stock logo
VNRX
VolitionRx
+0.81%-4.24%+7.97%-1.66%-17.18%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ainos, Inc. stock logo
AIMD
Ainos
$4.01
+3.6%
$3.45
$2.00
$5.00
$19.13M2.25830,296 shs89,210 shs
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
$0.76
+0.6%
$0.71
$0.61
$3.02
$36.08M3.24623,154 shs986,012 shs
LAVA Therapeutics N.V. stock logo
LVTX
LAVA Therapeutics
$1.58
-2.5%
$1.54
$0.85
$2.09
$41.56M0.5223,362 shs71,013 shs
VolitionRx Limited stock logo
VNRX
VolitionRx
$0.65
-0.3%
$0.65
$0.40
$0.94
$69.72M1.27200,549 shs193,514 shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ainos, Inc. stock logo
AIMD
Ainos
+0.26%+11.85%+10.89%+21.32%+57.93%
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
+8.57%+13.43%+12.06%-28.30%-23.05%
LAVA Therapeutics N.V. stock logo
LVTX
LAVA Therapeutics
+0.62%+3.85%+3.18%+19.12%-4.14%
VolitionRx Limited stock logo
VNRX
VolitionRx
+0.81%-4.24%+7.97%-1.66%-17.18%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ainos, Inc. stock logo
AIMD
Ainos
1.00
SellN/AN/A
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
2.00
Hold$9.001,076.78% Upside
LAVA Therapeutics N.V. stock logo
LVTX
LAVA Therapeutics
1.86
Reduce$2.6969.94% Upside
VolitionRx Limited stock logo
VNRX
VolitionRx
3.00
Buy$3.50440.12% Upside

Current Analyst Ratings Breakdown

Latest AIMD, ITRM, LVTX, and VNRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/8/2025
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
10/8/2025
LAVA Therapeutics N.V. stock logo
LVTX
LAVA Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/30/2025
VolitionRx Limited stock logo
VNRX
VolitionRx
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$2.50
9/29/2025
VolitionRx Limited stock logo
VNRX
VolitionRx
D. Boral Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$5.00
9/27/2025
Ainos, Inc. stock logo
AIMD
Ainos
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
9/27/2025
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/27/2025
LAVA Therapeutics N.V. stock logo
LVTX
LAVA Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/10/2025
VolitionRx Limited stock logo
VNRX
VolitionRx
D. Boral Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$5.00
8/15/2025
VolitionRx Limited stock logo
VNRX
VolitionRx
D. Boral Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$5.00
8/5/2025
LAVA Therapeutics N.V. stock logo
LVTX
LAVA Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetNeutral$1.50 ➝ $1.24
8/5/2025
LAVA Therapeutics N.V. stock logo
LVTX
LAVA Therapeutics
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuyHold$3.00 ➝ $1.50
(Data available from 10/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ainos, Inc. stock logo
AIMD
Ainos
$20K956.39N/AN/A$5.51 per share0.73
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
N/AN/AN/AN/A($0.15) per shareN/A
LAVA Therapeutics N.V. stock logo
LVTX
LAVA Therapeutics
$4.99M8.33N/AN/A$1.06 per share1.49
VolitionRx Limited stock logo
VNRX
VolitionRx
$1.32M52.85N/AN/A($0.11) per share-5.89
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ainos, Inc. stock logo
AIMD
Ainos
-$14.86M-$4.99N/AN/AN/A-108.25%-56.94%11/5/2025 (Estimated)
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
-$24.77M-$0.85N/AN/AN/AN/A-65.01%11/13/2025 (Estimated)
LAVA Therapeutics N.V. stock logo
LVTX
LAVA Therapeutics
-$25.11M-$1.05N/AN/AN/AN/A-106.29%-38.24%12/9/2025 (Estimated)
VolitionRx Limited stock logo
VNRX
VolitionRx
-$35.32M-$0.25N/AN/A-2,321.14%N/A-163.39%N/A

Latest AIMD, ITRM, LVTX, and VNRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
Ainos, Inc. stock logo
AIMD
Ainos
N/A-$0.99N/A-$0.99N/AN/A
8/13/2025Q2 2025
LAVA Therapeutics N.V. stock logo
LVTX
LAVA Therapeutics
-$0.28-$0.32-$0.04-$0.32N/AN/A
8/5/2025Q2 2025
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
-$0.13-$0.16-$0.03-$0.16N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Ainos, Inc. stock logo
AIMD
Ainos
N/AN/AN/AN/AN/A
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
N/AN/AN/AN/AN/A
LAVA Therapeutics N.V. stock logo
LVTX
LAVA Therapeutics
N/AN/AN/AN/AN/A
VolitionRx Limited stock logo
VNRX
VolitionRx
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ainos, Inc. stock logo
AIMD
Ainos
0.96
2.88
2.61
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
N/A
2.69
2.52
LAVA Therapeutics N.V. stock logo
LVTX
LAVA Therapeutics
N/A
10.78
10.78
VolitionRx Limited stock logo
VNRX
VolitionRx
N/A
0.22
0.22

Institutional Ownership

CompanyInstitutional Ownership
Ainos, Inc. stock logo
AIMD
Ainos
N/A
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
9.21%
LAVA Therapeutics N.V. stock logo
LVTX
LAVA Therapeutics
N/A
VolitionRx Limited stock logo
VNRX
VolitionRx
8.09%

Insider Ownership

CompanyInsider Ownership
Ainos, Inc. stock logo
AIMD
Ainos
10.39%
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
2.40%
LAVA Therapeutics N.V. stock logo
LVTX
LAVA Therapeutics
9.50%
VolitionRx Limited stock logo
VNRX
VolitionRx
10.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ainos, Inc. stock logo
AIMD
Ainos
404.77 million4.28 millionNot Optionable
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
1047.17 million46.04 millionNot Optionable
LAVA Therapeutics N.V. stock logo
LVTX
LAVA Therapeutics
6026.31 million23.81 millionOptionable
VolitionRx Limited stock logo
VNRX
VolitionRx
80107.60 million80.80 millionOptionable

Recent News About These Companies

Volition Sponsors Upcoming GenomeWeb Webinar
HC Wainwright Reiterates "Buy" Rating for VolitionRx (NYSE:VNRX)
Volition Signs First Human Out Licensing Deal
Insights into VolitionRX's Upcoming Earnings
VolitionRx Limited (VNRX) - Yahoo Finance

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ainos stock logo

Ainos NASDAQ:AIMD

$4.01 +0.14 (+3.62%)
As of 04:00 PM Eastern

Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.

Iterum Therapeutics stock logo

Iterum Therapeutics NASDAQ:ITRM

$0.76 +0.00 (+0.63%)
Closing price 04:00 PM Eastern
Extended Trading
$0.75 -0.01 (-1.80%)
As of 05:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

LAVA Therapeutics stock logo

LAVA Therapeutics NASDAQ:LVTX

$1.58 -0.04 (-2.47%)
Closing price 04:00 PM Eastern
Extended Trading
$1.59 +0.01 (+0.63%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.

VolitionRx stock logo

VolitionRx NYSE:VNRX

$0.65 0.00 (-0.31%)
Closing price 04:00 PM Eastern
Extended Trading
$0.66 +0.01 (+1.54%)
As of 05:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.